Home/Pipeline/OVT-201

OVT-201

Solid Tumors

DiscoveryActive

Key Facts

Indication

Solid Tumors

Phase

Discovery

Status

Active

Company

OverT Bio

About OverT Bio

OverT Bio is a private, pre-clinical stage biotech founded in 2021, headquartered in San Diego, CA, with a secondary office in New York, NY. The company is developing a differentiated platform that integrates AI-driven functional genomics, multimodal receptor design, and gamma delta T cells to create off-the-shelf cell therapies targeting solid tumors. With a lead program, OVT-101, anticipated to enter first-in-human trials in H1 2027, OverT aims to overcome key challenges in solid tumor treatment such as immunosuppression, poor T cell persistence, and manufacturing scalability. The company is backed by venture capital and strategic collaborators.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed